Optimizing Research With Diverse Families - Feasibility and Acceptability Study (FAST)
A Feasibility and Acceptability Study (FAST) to Optimize Research Methodology in a Multinutrient Study of Racially and Ethnically Diverse Children With ADHD and Emotional Dysregulation
Oregon Health and Science University
30 participants
Jan 6, 2024
INTERVENTIONAL
Conditions
Summary
Evaluate feasibility and acceptability of recruiting Black and Hispanic families for an open label clinical trial of multinutrients while collecting real-time parent-reported child behavior data and collecting at-home biospecimens to explore their potential as biomarkers, in a study of pediatric ADHD.
Eligibility
Inclusion Criteria7
- Children, ages 6-17 years at enrollment, with suspected or definite ADHD based on parent report in a majority of families that identify as Black or Hispanic or multicultural
- Meet criteria on Child and Adolescent Symptom Inventory-5 (CASI-5) ADHD scale (6+ symptoms ≥ 2), occurring in >1 setting, plus one impairing irritability symptom (≥2) from Oppositional Defiant Disorder (ODD) or Disruptive Mood Dysregulation Disorder (DMDD) subscale
- Able and willing to swallow up to 8 pills per day
- Medication free for 2 weeks prior to baseline
- Willing to use Tasso® OnDemand SST+ to collect blood at home and filter cards to provide urine samples
- Able to communicate in English
- Parent/care giver identifies child as Black/African American or Hispanic/Latina/o or more than one race (target 70-100%)
Exclusion Criteria6
- Neurological disorders
- Medical conditions (e.g. cancer, kidney or liver disease, diabetes, hyperthyroidism)
- Psychiatric conditions requiring hospitalization
- Allergy to any supplement ingredient
- In people with a uterus: sexually active, pregnancy or suspected pregnancy
- Abnormality of mineral metabolism
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Participants will take 2-4 capsules of EMP+ Advanced per day (max 8 capsules) for eight weeks.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06133231